NY-QUARTILE
13.12.2021 19:02:04 CET | Business Wire | Press release
Quartile , the leading ad optimization platform for top e-commerce marketplace sellers, today announced it has acquired Sidecar , a performance marketing technology provider for e-commerce retailers and brands that works across all major advertising platforms , including Google, Microsoft Bing, Facebook, Instagram, and Amazon.
The two companies will combine under the Quartile name, growing the brand into the world’s largest cross-channel e-commerce advertising platform. Both platforms apply machine-learning and natural-language processing to provide data-driven strategies and best practices to brand marketers while also offering best-in-class reporting and ad management.
Quartile expects the acquisition to double its amount of advertising spend under management across all platforms to $2 billion in 2021. Unilever, Burt’s Bees and Thrasio are among the more than 5,000 brands currently using the platforms on e-commerce channels like Amazon, Google, Instacart, Walmart, Facebook and Shopify. The combined company will have clients across 26 countries.
"By combining Sidecar's best-in-class solution and expertise managing campaigns for DTC e-commerce merchants with our proprietary AI-driven analytics and optimization platform, we will create the most comprehensive and powerful e-commerce suite," said Daniel Knijnik, co-founder and CEO at Quartile. “The two companies’ complementary businesses, products and relationships will offer unrivaled benefits for our combined customers, employees and other stakeholders across a diverse set of markets.”
"Retail marketers and small businesses are up against great odds when it comes to being seen in online marketplaces. Only 0.1% of products account for around 80% of the sales on e-commerce marketplaces, so brands recognize they need a holistic solution to help them compete in all marketplaces and direct-to-consumer websites,” added Knijnik.
Both Quartile and Sidecar have witnessed exponential growth in recent years as fiercer competition among e-commerce merchants has led to increased advertising spend. Amazon is predicted to grow its ad revenue to $24.47 billion by the end of 2021, an increase of 55.5% year over year, closing the gap as the world's third-largest ad network after Google and Facebook (whose ad revenues grew 34% and 43% , respectively). The platforms provide e-commerce marketers with a critical edge in this fast growing industry.
"We share a passion with the Quartile team for helping small businesses and large retailers grow their exposure, shopping audience, and brands across channels," said Andre Golsorkhi, founder and CEO of Sidecar. "This acquisition is the ultimate example of how we continue to dig in for our customers as their challenges become more complex. By combining the aptitudes and technologies of Sidecar and Quartile, we are continuing to ensure the performance marketing excellence that retailers rely on us for.”
Terms of the acquisition were not disclosed. The combined businesses will comprise a team of more than 300 personnel. Rockbridge Growth Equity, a Detroit-based private equity firm which originally invested a minority stake in Quartile in September of last year, will remain the lead institutional investor in the transaction. Existing Sidecar shareholders will also own a significant stake of the post-acquisition Quartile entity. Investment Bank Canaccord Genuity served as the exclusive financial advisor to Quartile and Rockbridge in connection with the transaction.
“We are thrilled to be partnering with the Sidecar team,” said Kevin Prokop, founder and managing partner at Rockbridge. “The Sidecar team has built an exceptional business. We believe the combination of Quartile and Sidecar creates a distinctive company that is uniquely positioned to capture the exciting opportunities in the e-commerce marketing industry.”
About Quartile:
Founded in 2016, Quartile is an artificial intelligence and machine learning-powered ad optimization platform for leading e-commerce marketplace sellers, such as Amazon, Walmart.com, and Instacart. Quartile’s advertising technology uses proprietary technology and six patented algorithms to make real-time decisions based on accurate data for improved performance and growth. The Quartile platform is an easy-to-use dashboard that equips sellers with the tools to manage their retail media in every marketplace, enabling them to optimize campaigns at the product level to maximize sales, lower the advertising cost of sale (ACoS), and improve margins. For more information visit: www.quartile.com .
About Sidecar:
Sidecar offers performance marketing excellence to retailers and brands. Sidecar’s advanced technology and proprietary data, combined with years of performance marketing expertise, help its customers unlock the full potential of today’s most powerful search, shopping, social, and marketplace channels. For more information, visit: getsidecar.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005819/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
